Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead, JAKed About Cancer Research, Buys YM BioScienses

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead will buy the Canadian cancer specialist for $510 million, gaining the lead drug CYT387, a JAK1/JAK2 inhibitor that has demonstrated positive results in myelofibrosis patients.

You may also be interested in...



Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib

With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.

Deal Activity Highlights Interest In Bispecific Antibodies

Bispecific antibodies can be developed using many different formats for multiple therapeutic areas (see related story, (Also see "Is The Time Finally Right For Bispecific Antibodies?" - Pink Sheet, 16 Apr, 2013.)). Big pharmas have inked deals with modest upfront payments to explore the use of a variety of technology applications.

A Face-Off With Gilead? Incyte Execs Are Upbeat About Jakafi

Gilead’s looming entrance into the increasingly competitive myelofibrosis market doesn’t phase Incyte executives, who remain upbeat about their first-in-class MF drug Jakafi. More than a year after its launch in November 2011, they point to new data demonstrating the drug’s overall survival benefits and greater clarity around optimal titration.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS073624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel